Compare Roundhill Magnificent Seven ETF (MAGS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Nuwellis Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.33 (market cap $5.78B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Roundhill Magnificent Seven ETF is far larger — about 2627.3× Nuwellis Inc's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Nuwellis Inc for 26 Days on average.
| MAGS | NUWE | |
|---|---|---|
Market Cap | $5.78B | $2.20M |
Volume | 4,410,665 | 121,544 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $146.65 |
52-Week Low | $55.39 | $0.68 |
Typical Hold Time | 36 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to seven mega-cap tech leaders and has delivered 181% returns since launch, though it trails the S&P 500 in 2026 with just 2% YTD gains. Recent news highlights AI-driven momentum but also concerns about the 'Magnificent Seven' theme fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but investors face concentration risk in tech and underperformance versus broader markets. Key risks include aggressive AI spending impacting cash flows and shifting investor preference toward semiconductors. Analyst sentiment is mixed, balancing long-term growth prospects against near-term valuation concerns and market rotation trends.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
